Infliximab and Classic DMARDs in the Rheumatoid Arthritis Patients
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
A prospective, multi-centric, cohort study to observe the efficacy difference between
intensive classic DMARDs and Infliximab(IFX) with methotrexate(MTX) treatment in sever
rheumatoid arthritis(RA) 28 joints disease activity score>5.1(DAS28>5.1) patients with poor
prognostic factors.Primary objective is compare the difference of clinical remission rate
between classic DMARDs and Infliximab with MTX treatment in severe RA patients with poor
prognostic factors at week 30.
Phase:
N/A
Details
Lead Sponsor:
Zhang, Xiao, M.D.
Collaborators:
Central South University Tianjin Medical University General Hospital Xijing Hospital